Reata Pharmaceuticals, Inc. / Fundamentals
Income statement
- Net revenue
€20.93M - Cost of goods sold
€725.87K - Gross profit
€20.21M - SG&A expenses
€137.17M - R&D expenses
€174.44M - EBITDA
-€87.91M - D&A
€969.54K - EBIT
-€51.03M - Interest expenses
€34.85M - EBT
-€75.23M - Tax expenses
€212.78K - Net income
-€68.69M
Cash flow statement
- Net deferred tax
-€250.51M - Non-cash items
€29.55M - Changes in working capital
€6.73M - Operating cash flow
-€213.07M - Capex
€963.53K - Other investing cash flow
€0.00 - Net investing cash flow
€50.98M - Total cash dividends paid
€0.00 - Issuance of common stock
€191.10M - Debt repayment
€0.00 - Other financing cash flow
€11.87M - Net financing cash flow
€77.74M - Foreign exchange effects
€144.12M - Net change in cash
-€84.35M - Cash at end of period
€41.91M - Free cash flow
-€212.11M
Balance sheet
- Cash and cash equivalents
€41.91M - Cash and short-term investments
€283.32M - Total receivables
€19.44M - Inventory
€2.52M - Other current assets
€39.49M - Total current assets
€344.79M - Property, plant & equipment
€77.14M - Goodwill
€0.00 - Intangible assets
€0.00 - Long-term investments
€0.00 - Other non-current assets
€9.30M - Total non-current assets
€86.43M - Total assets
€431.22M - Accounts payable
€17.04M - Short-term debt
€2.11M - Other current liabilities
€88.18M - Total current liabilities
€107.33M - Long-term debt
€77.58M - Deferred tax liabilities
€0.00 - Other non-current liabilities
€171.42M - Total non-current liabilities
€248.99M - Total liabilities
€356.32M - Common stock
€32.60K - Retained earnings
-€1.28B - Other equity
€0.00 - Total equity
€74.90M - Total liabilities and shareholders' equity
€431.22M
Company information
- Market capitalization
€5.60B - Employees
321 - Enterprise Value
€6.64B
Company ratios
- Gross margin
-
96.5% Much better than peer group: -2,366.1% - EBITDA margin
-
-420.0% Much better than peer group: -5,431.3% - EBIT margin
-
-243.8% Much better than peer group: -6,014.5% - EBT margin
-
-359.4% Much better than peer group: -6,607.9% - Net margin
-
-328.2% Much better than peer group: -6,024.4% - ROE
-
-91.7% Much better than peer group: -121.1% - ROA
-
-15.9% Much better than peer group: -406.1% - Asset turnover
-
4.9% Worse than peer group: 15.0% - FCF margin
-
-1,022.6% Much better than peer group: -4,622.5% - FCF yield
-3.8% - Efficiency ratio
520.0% - Net sales per employee
-
€65.21K - Net income per employee
-
-€213.98K